Summit Therapeutics Inc. to hold special meeting
- Special meeting on November 4, 2026
- Proposal to increase authorized shares by 1,000,000,000
- Record date for voting is October 1, 2026
DEF 14A
DEF 14A: Definitive Proxy Statement
The proxy statement goes to shareholders before a meeting. It covers director elections, executive compensation, say-on-pay and shareholder proposals.
Inside the DEF 14A
- Board nominees and governance
- Executive pay tables
- Proposals put to a shareholder vote
Latest DEF 14A stories
No DEF 14A stories yet.
Latest DEF 14A filings
DEF 14ASummit Therapeutics Inc.SMMTLIVE DEF 14AFuture FinTech Group Inc.FTFTLIVE Future FinTech Group Inc. reports $3.34 million net loss
- Net loss of $3.34 million for the year ended Dec 31, 2025
- Annual meeting scheduled for Nov 19, 2026
- Board recommends voting for director nominees and amendments
DEF 14ALISATA THERAPEUTICS, INC.LSTALIVE Lisata Therapeutics reports $17M net loss
- Net loss of $17 million for the year ended Dec 31, 2025
- Acquired Marea Therapeutics on Sep 17, 2026
- Issued 1,793,129 shares of common stock to Marea shareholders
DEF 14ATesla, Inc.TSLALIVE Tesla reports $3.85B net income for 2025
- Net income: $3.85 billion for the year ended Dec 31, 2025
- Cybercab production started at Gigafactory Texas
- Robotaxi service expanded to more U.S. cities
DEF 14ABeneficientBENFLIVE BENF to hold special meeting on Oct 29
- Special meeting date: Oct 29, 2026
- Proposal to approve Yorkville share issuance
- Proposal to adjourn meeting if needed
DEF 14ABIOLARGO, INC.BLGOLIVE BLGO reports $15.19M net loss for 2025
- Net loss of $15.19 million for the year ended Dec 31, 2025
- Annual meeting scheduled for Dec 1, 2026
- Seven directors nominated for election